Lung Cancer News and Research

Latest Lung Cancer News and Research

New mathematical model forecasts metastatic breast cancer survival rates

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.

24 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Researchers successfully create infinitely reproducing tissue cultures

Most cases of small cell lung cancer are only diagnosed after the tumour has already formed metastases. Until now it has not been possible to investigate the reasons for this rapid metastasis, because of a lack of sufficient tumour material from patients. Now, the group of researchers led by Gerhard Hamilton, University Department of Surgery at Medical University of Vienna has succeeded in creating infinitely reproducing tissue cultures.

22 Nov 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015

Mason researchers patent new breast cancer treatment

George Mason University researchers have patented a new breast cancer treatment that uses a common malaria drug to stop cancer in its beginning stages.

21 Nov 2015

VolitionRx's NuQ blood tests accurately detect more than 90% of lung cancer cases

VolitionRx Limited today announced interim data demonstrating its NuQ blood tests have accurately detected more than 90% of lung cancer cases in a study of 73 patients.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Georgia State University researchers develop a method to better trace and treat cancer

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed by Georgia State University researchers.

18 Nov 2015

Living with lung cancer: an interview with Aoife McNamara

Understanding how lung cancer affects patients from a social perspective is vital. People living with lung cancer, lung cancer survivors and carers are impacted by lung cancer in different ways.

18 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

17 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.

13 Nov 2015

New RNA test of blood platelets can be used to detect location of cancer

A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood. Using this new method for blood-based RNA tests of blood platelets, researchers have been able to identify cancer with 96 per cent accuracy. This according to a study at Umeå University in Sweden recently published in the journal Cancer Cell.

12 Nov 2015

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.

12 Nov 2015

Biocept receives European patent covering antibody usage in capture of rare cells

Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that the European Patent Office has awarded the patent, "DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS," as announced in the European Bulletin dated November 11, 2015.

11 Nov 2015

Surgical lung resection can improve outcomes in high-risk patients with early stage disease

Surgical lung resection, in which part of a lung is removed, can be a safe and effective treatment option for high-risk patients with early stage lung cancer, according to an article posted online by The Annals of Thoracic Surgery.

11 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

New mathematical model forecasts metastatic breast cancer survival rates

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Researchers successfully create infinitely reproducing tissue cultures

Crucial tumor-suppressing gene protects immune attack against lung cancer

Mason researchers patent new breast cancer treatment

VolitionRx's NuQ blood tests accurately detect more than 90% of lung cancer cases

Lilly, Merck expand oncology clinical trial collaboration

Georgia State University researchers develop a method to better trace and treat cancer

Living with lung cancer: an interview with Aoife McNamara

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Patients with kidney failure at increased risk of developing different types of cancer

New RNA test of blood platelets can be used to detect location of cancer

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

Biocept receives European patent covering antibody usage in capture of rare cells

Surgical lung resection can improve outcomes in high-risk patients with early stage disease

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

AACR rapid and dramatic responses in TRK fusion patients

Viralytics enters into clinical trial collaboration agreement with MSD

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in